February 21, 2024 – Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary stable production system from biotechnology leader CSL.
Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to cutting edge technology for stable and scalable high-titer clinical lentivirus production.
Read the full press release here.
